Oral Oncolytics Market

Oral Oncolytics Series: Leukemia, 2014 - 2024

  • Lowest Price Guaranteed From USD 1,899

  • Companies Covered

  • Pages

  • View Count

Oral Oncolytics Market Overview

Targeted therapeutics is fast emerging as the key focus area in biopharmaceutical industry. Oral targeted therapeutics has attracted many drug developers due to the ease of administration it offers to patients (especially pediatric and geriatric patients). In the case of leukemia, current marketed oral drugs include Gleevec, Tasigna, Sprycel, Bosulif, Imbruvica and Iclusig.

The high price of these drugs still remains a major constraint to the market growth. Further, as leukemia accounts for about 3% of all cancer cases per year, most of the companies are targeting other cancer indications offering a wider market prospective. The oral targeted drugs market is expected to be driven by new generation and new class of inhibitors. Several pharmaceutical companies, both big and small, are looking to capture a share of the leukemia market, where orally delivered drugs are well accepted.

Despite the impending patent expiry of some drugs (especially Gleevec), the market is set to rise after a likely dip in growth rate in the short-term. There are specific opportunities which remain to be tapped in the mid-long term; emerging drug therapies such as third generation tyrosine kinase inhibitors (TKIs), multi kinase inhibitors, FLT3 inhibitors, AKT kinase inhibitors and BTK inhibitors are likely to sustain the interest of drug makers.

Scope of the Report

The ‘Oral Oncolytics Series: Leukemia, 2014 - 2024’ report provides an extensive study of the market of oral targeted leukemia drugs, specifically focusing on currently commercialized drugs, those under development and the likely future market evolution. Targeted therapeutics have tremendous potential and the market is expected to grow steadily over the coming few years. The focus of our report is on drugs which target a specific marker / antigen on leukemia cells and are delivered through mouth. The report covers various aspects such as regulatory approvals, treatment cost, historical sales, product pipeline and industry research programs.

With the upcoming patent expiry of some well-known drugs, we have looked at how the market landscape is likely to change in the coming years. In fact, one of the key objectives of this report is to understand the current and future state of the oral targeted leukemia drugs. This is done by analyzing the following:

  • Marketed oral targeted leukemia drugs
  • Products in pipeline
  • Competing technologies and innovations
  • Growing target patient pool

The base year for the report is 2013. The report provides short-mid term and long term forecasts for the period 2014 - 2024. This forecast is supported by detailed research and analysis of drugs (both marketed / pipeline) which we believe will have a far-reaching impact on the market. Owing to the uncertainties associated with drug development and customer adoption trends, we have presented three different market scenarios for each of the drugs studied in this exercise:

  • Conservative Scenario: This represents our most pessimistic view of the success / adoption of each individual drug.
  • Base Scenario: This represents the most-likely success / adoption of respective drugs.
  • Aggressive Scenario: This is the bullish scenario wherein we have been aggressive in terms of the penetration rates of respective drugs and the likely market size.


This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com